For a second year in a row, Currax delivered greater than 50% year-over-year revenue growth for CONTRAVE®/MYSIMBA® in 2024. These outsized results were driven by increased patient demand, improved ...

including the number one branded oral weight loss medication CONTRAVE ® (naltrexone HCl/bupropion HCl), today announces 2024 over-performance for revenue, demand and achievement of key ...

Currax Pharmaceuticals LLC ("Currax"), a specialty Pharmaceutical company with over 25 products, including the number one branded oral weight loss medication CONTRAVE® (naltrexone HCl/bupropion ...

While shares of Tech Mahindra, TCS, Persistent Systems, Infosys, Mphasis, HCL Tech, LTIMindtree and Coforge are down by 1% to 2%. The bearish tone in IT stocks comes ahead of Q3 results season.